Literature DB >> 29329637

Transcriptomic evidence of immune activation in macroscopically normal-appearing and scarred lung tissues in idiopathic pulmonary fibrosis.

Irina G Luzina1, Mariah V Salcedo1, Mónica L Rojas-Peña2, Anne E Wyman1, Jeffrey R Galvin3, Ashutosh Sachdeva3, Andrew Clerman3, June Kim3, Teri J Franks4, Edward J Britt3, Jeffrey D Hasday1, Si M Pham3, Allen P Burke3, Nevins W Todd1, Sergei P Atamas5.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease manifested by overtly scarred peripheral and basilar regions and more normal-appearing central lung areas. Lung tissues from macroscopically normal-appearing (IPFn) and scarred (IPFs) areas of explanted IPF lungs were analyzed by RNASeq and compared with healthy control (HC) lung tissues. There were profound transcriptomic changes in IPFn compared with HC tissues, which included elevated expression of numerous immune-, inflammation-, and extracellular matrix-related mRNAs, and these changes were similar to those observed with IPFs compared to HC. Comparing IPFn directly to IPFs, elevated expression of epithelial mucociliary mRNAs was observed in the IPFs tissues. Thus, despite the known geographic tissue heterogeneity in IPF, the entire lung is actively involved in the disease process, and demonstrates pronounced elevated expression of numerous immune-related genes. Differences between normal-appearing and scarred tissues may thus be driven by deranged epithelial homeostasis or possibly non-transcriptomic factors. Published by Elsevier Inc.

Entities:  

Keywords:  Fibrosis; Inflammation; Lung; Transcriptome

Mesh:

Substances:

Year:  2018        PMID: 29329637      PMCID: PMC5826809          DOI: 10.1016/j.cellimm.2018.01.002

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  62 in total

1.  Gene expression profiling in the lungs of patients with pulmonary hypertension associated with pulmonary fibrosis.

Authors:  Marco Mura; Masaki Anraku; Zhihong Yun; Karen McRae; Mingyao Liu; Thomas K Waddell; Lianne G Singer; John T Granton; Shaf Keshavjee; Marc de Perrot
Journal:  Chest       Date:  2011-08-11       Impact factor: 9.410

2.  Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society.

Authors:  B Bradley; H M Branley; J J Egan; M S Greaves; D M Hansell; N K Harrison; N Hirani; R Hubbard; F Lake; A B Millar; W A H Wallace; A U Wells; M K Whyte; M L Wilsher
Journal:  Thorax       Date:  2008-09       Impact factor: 9.139

3.  Characterizing the molecular spatial and temporal field of injury in early-stage smoker non-small cell lung cancer patients after definitive surgery by expression profiling.

Authors:  Humam Kadara; Li Shen; Junya Fujimoto; Pierre Saintigny; Chi-Wan Chow; Wenhua Lang; Zuoming Chu; Melinda Garcia; Mohamed Kabbout; You-Hong Fan; Carmen Behrens; Diane A Liu; Li Mao; J Jack Lee; Kathryn A Gold; Jing Wang; Kevin R Coombes; Edward S Kim; Waun Ki Hong; Ignacio I Wistuba
Journal:  Cancer Prev Res (Phila)       Date:  2012-10-19

4.  Expression of cilium-associated genes defines novel molecular subtypes of idiopathic pulmonary fibrosis.

Authors:  Ivana V Yang; Christopher D Coldren; Sonia M Leach; Max A Seibold; Elissa Murphy; Jia Lin; Rachel Rosen; Amanda J Neidermyer; David F McKean; Steve D Groshong; Carlyne Cool; Gregory P Cosgrove; David A Lynch; Kevin K Brown; Marvin I Schwarz; Tasha E Fingerlin; David A Schwartz
Journal:  Thorax       Date:  2013-06-19       Impact factor: 9.139

5.  Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis.

Authors:  Annie Pardo; Kevin Gibson; José Cisneros; Thomas J Richards; Yinke Yang; Carina Becerril; Samueal Yousem; Iliana Herrera; Victor Ruiz; Moisés Selman; Naftali Kaminski
Journal:  PLoS Med       Date:  2005-09-06       Impact factor: 11.069

6.  MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis.

Authors:  Ivan O Rosas; Thomas J Richards; Kazuhisa Konishi; Yingze Zhang; Kevin Gibson; Anna E Lokshin; Kathleen O Lindell; Jose Cisneros; Sandra D Macdonald; Annie Pardo; Frank Sciurba; James Dauber; Moises Selman; Bernadette R Gochuico; Naftali Kaminski
Journal:  PLoS Med       Date:  2008-04-29       Impact factor: 11.069

7.  HTSeq--a Python framework to work with high-throughput sequencing data.

Authors:  Simon Anders; Paul Theodor Pyl; Wolfgang Huber
Journal:  Bioinformatics       Date:  2014-09-25       Impact factor: 6.937

8.  Upregulation of interleukin-33 and thymic stromal lymphopoietin levels in the lungs of idiopathic pulmonary fibrosis.

Authors:  Jong-Uk Lee; Hun Soo Chang; Hyeon Ju Lee; Chang An Jung; Da Jeong Bae; Hyun Ji Song; Jong Sook Park; Soo-Taek Uh; Young Hoon Kim; Ki-Hyun Seo; Choon-Sik Park
Journal:  BMC Pulm Med       Date:  2017-02-15       Impact factor: 3.317

9.  Detecting splicing variants in idiopathic pulmonary fibrosis from non-differentially expressed genes.

Authors:  Nan Deng; Cecilia G Sanchez; Joseph A Lasky; Dongxiao Zhu
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240

10.  The idiopathic pulmonary fibrosis honeycomb cyst contains a mucocilary pseudostratified epithelium.

Authors:  Max A Seibold; Russell W Smith; Cydney Urbanek; Steve D Groshong; Gregory P Cosgrove; Kevin K Brown; Marvin I Schwarz; David A Schwartz; Susan D Reynolds
Journal:  PLoS One       Date:  2013-03-20       Impact factor: 3.240

View more
  23 in total

Review 1.  New therapeutics based on emerging concepts in pulmonary fibrosis.

Authors:  Vishwaraj Sontake; Prathibha R Gajjala; Rajesh K Kasam; Satish K Madala
Journal:  Expert Opin Ther Targets       Date:  2018-11-28       Impact factor: 6.902

2.  Wilms' tumor 1 drives fibroproliferation and myofibroblast transformation in severe fibrotic lung disease.

Authors:  Vishwaraj Sontake; Rajesh K Kasam; Debora Sinner; Thomas R Korfhagen; Geereddy B Reddy; Eric S White; Anil G Jegga; Satish K Madala
Journal:  JCI Insight       Date:  2018-08-23

3.  Transcriptional regulatory model of fibrosis progression in the human lung.

Authors:  John E McDonough; Farida Ahangari; Qin Li; Siddhartha Jain; Stijn E Verleden; Jose Herazo-Maya; Milica Vukmirovic; Giuseppe DeIuliis; Argyrios Tzouvelekis; Naoya Tanabe; Fanny Chu; Xiting Yan; Johny Verschakelen; Robert J Homer; Dimitris V Manatakis; Junke Zhang; Jun Ding; Karen Maes; Laurens De Sadeleer; Robin Vos; Arne Neyrinck; Panayiotis V Benos; Ziv Bar-Joseph; Dean Tantin; James C Hogg; Bart M Vanaudenaerde; Wim A Wuyts; Naftali Kaminski
Journal:  JCI Insight       Date:  2019-11-14

4.  Modeling of Fibrotic Lung Disease Using 3D Organoids Derived from Human Pluripotent Stem Cells.

Authors:  Alexandros Strikoudis; Anna Cieślak; Lucas Loffredo; Ya-Wen Chen; Nina Patel; Anjali Saqi; David J Lederer; Hans-Willem Snoeck
Journal:  Cell Rep       Date:  2019-06-18       Impact factor: 9.423

5.  Integrative omics analysis identifies biomarkers of idiopathic pulmonary fibrosis.

Authors:  Peiyan Zheng; Shixue Sun; Jingxian Wang; Xiaohua Douglas Zhang; Baoqing Sun; Zhangkai Jason Cheng; Kuan Cheok Lei; Mingshan Xue; Teng Zhang; Huimin Huang
Journal:  Cell Mol Life Sci       Date:  2022-01-11       Impact factor: 9.261

6.  Leveraging Therapy-Specific Polygenic Risk Scores to Predict Restrictive Lung Defects in Childhood Cancer Survivors.

Authors:  Daniel A Mulrooney; Yutaka Yasui; Cindy Im; Yan Yuan; Eric D Austin; Dennis C Stokes; Matthew J Krasin; Andrew M Davidoff; Yadav Sapkota; Zhaoming Wang; Kirsten K Ness; Carmen L Wilson; Gregory T Armstrong; Melissa M Hudson; Leslie L Robison
Journal:  Cancer Res       Date:  2022-08-16       Impact factor: 13.312

7.  Asthma and Post-Asthmatic Fibrosis: A Search for New Promising Molecular Markers of Transition from Acute Inflammation to Pulmonary Fibrosis.

Authors:  Innokenty A Savin; Andrey V Markov; Marina A Zenkova; Aleksandra V Sen'kova
Journal:  Biomedicines       Date:  2022-04-28

8.  Digital quantification of p16-positive foci in fibrotic interstitial lung disease is associated with a phenotype of idiopathic pulmonary fibrosis with reduced survival.

Authors:  Jonathan Keow; Matthew J Cecchini; Nathashi Jayawardena; Maurizio Zompatori; Mariamma G Joseph; Marco Mura
Journal:  Respir Res       Date:  2022-06-07

9.  Identification and Validation of Potential Biomarkers and Pathways for Idiopathic Pulmonary Fibrosis by Comprehensive Bioinformatics Analysis.

Authors:  Weibin Qian; Xinrui Cai; Qiuhai Qian; Xinying Zhang
Journal:  Biomed Res Int       Date:  2021-07-04       Impact factor: 3.411

10.  Transcriptomic and Epigenetic Profiling of Fibroblasts in Idiopathic Pulmonary Fibrosis.

Authors:  Ankit Hanmandlu; Lisha Zhu; Tinne C J Mertens; Scott Collum; Weizhen Bi; Feng Xiong; Ruoyu Wang; Rajarajan T Amirthalingam; Dewei Ren; Leng Han; Soma S S K Jyothula; Wenbo Li; W Jim Zheng; Harry Karmouty-Quintana
Journal:  Am J Respir Cell Mol Biol       Date:  2022-01       Impact factor: 7.748

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.